If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ETSAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Qu ...

Harmony Biosciences (HRMY) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Good morning. My name is Angela and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences First Quarter twenty twenty five Financial Results Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Please be advised that today's conference may be recorded. ...

Core Insights - Kraig Biocraft Laboratories, Inc. is successfully progressing towards its 2025 production scale-up targets, having completed its March/April spider silk production run and currently advancing in its May production cycle [1][3][4] Group 1: Production Progress - The company has met internal performance benchmarks and production targets for March and April, indicating confidence in its expanded capacity and workflow improvements [3][4] - May's production is already in progress, maintaining momentum towards achieving full-year production capacity goals [4][5] Group 2: Strategic Goals - Kraig Labs aims to transition recombinant spider silk from pilot-scale production to commercial viability across multiple markets, supporting its broader strategy [4][5] - The company emphasizes the importance of consistent execution and focus from its teams in Vietnam and the U.S. to strengthen manufacturing capabilities [5] Group 3: Company Background - Kraig Biocraft Laboratories is recognized as a leading developer of genetically engineered spider silk-based fiber technologies, with significant scientific breakthroughs impacting the global textile industry [7]

NEW YORK, May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/p ...

分组1 - ImmunityBio, Inc. (NASDAQ: IBRX) received a Refusal to File (RTF) letter from the FDA regarding its supplemental Biologics License Application (sBLA) for Anktiva in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer [1] - The RTF letter indicates that the FDA found issues with the submission that need to be addressed before the application can be considered [1] - This development may impact the company's stock performance and investor sentiment in the biotech sector [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Adverum Biotechnologies, Inc. following the company's announcement of the need to restate its financial statements due to accounting errors [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Adverum and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1]. - The investigation was prompted by Adverum's disclosure that certain previously issued financial statements should no longer be relied upon due to non-cash errors related to tenant improvement allowances [3]. Group 2: Financial Impact - On March 31, 2025, Adverum announced it would restate its financial statements for the years ended December 31, 2022 and 2023, as well as unaudited quarterly financial information for 2023 and 2024 [3]. - Following the announcement, Adverum's stock price dropped by $0.54 per share, representing a decline of 12.36%, closing at $3.83 per share on April 1, 2025 [3]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zl ...

Summary⚈ Congresswoman April McClain Delaney bought Bio-Techne stock twice in April 2025.⚈ The stock has dropped nearly 30% year-to-date and remains unprofitable post-purchase.⚈ Delaney’s committee roles suggest potential informational advantages in biotech-related decisions.Finbold’s congressional trading radar has recently picked up a suspicious stock bet made by Maryland congresswoman April McClain Delaney involving a low-profile biotech stock. The representative purchased Bio-Techne Corp stock (NASDAQ: ...

Company Overview - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that address serious diseases by correcting abnormal gene expression [1][3] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate drug targets within the chromatin regulatory system, with an initial emphasis on oncology [3] Upcoming Events - Management will participate in the Citizens Life Sciences Conference on May 7-8, 2025, in New York, NY, with a presentation scheduled for May 7, 2025, at 9:30 a.m. EST by CEO Adrian Gottschalk [1][2] - In addition to the conference, management will engage in one-on-one meetings on the same day [2] Product Development - Foghorn Therapeutics is developing multiple product candidates aimed at treating genetically determined dependencies within the chromatin regulatory system, particularly in the oncology sector [3] - The company's broad pipeline has the potential to significantly impact the lives of patients suffering from a variety of diseases [1]